Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides

The pharmacokinetics and renal excretion of the sulphonamides sulphachloropyridazine, sulphadiazine, sulphaisodimidine, sulphamerazine, and sulphamethoxazole were investigated in a cross-over study with doses of 800 mg each. The serum half-life, urine levels, distribution volume, protein binding and...

Full description

Saved in:
Bibliographic Details
Published in:Infection 1979-07, Vol.7 Suppl 4 (S4), p.S367-S370
Main Authors: Ortengren, B, Fellner, H, Bergan, T
Format: Article
Language:English
Subjects:
Adult
Drug Combinations
Female
Half-Life
Humans
Kinetics
Sulfachlorpyridazine - pharmacology
Sulfadiazine - pharmacology
Sulfamerazine - pharmacology
Sulfamethazine - pharmacology
Sulfamethoxazole - pharmacology
Sulfonamides - pharmacology
Sulfonamides - urine
Trimethoprim - pharmacology
Urinary Tract Infections - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pharmacokinetics and renal excretion of the sulphonamides sulphachloropyridazine, sulphadiazine, sulphaisodimidine, sulphamerazine, and sulphamethoxazole were investigated in a cross-over study with doses of 800 mg each. The serum half-life, urine levels, distribution volume, protein binding and potential antibacterial activity in the urine renders sulphadiazine the preferred component in a combination tablet together with trimethoprim for the treatment of urinary tract infections.
ISSN:0300-8126
1439-0973
DOI:10.1007/BF01639015